BCAT1 divergent transcript (BCAT1-DT)

The **BCAT1 divergent transcript (BCAT1-DT)**, also called **lnc-BCAT1**, is a long non-coding RNA gene at the BCAT1 locus, distinct from the protein-coding BCAT1 gene. There is currently no substantial evidence for biological function, disease association, or therapeutic relevance of BCAT1-DT in the literature. It is frequently conflated with BCAT1, a cytosolic enzyme involved in branched-chain amino acid metabolism and widely studied as an oncogenic factor in cancer progression[1][2][3][5][6][7]. No drugs, biomarkers, or safety concerns are documented for BCAT1-DT, and its molecular and clinical significance remains largely uncharacterized[4]. **Key distinction:** Most of the published research relates to **BCAT1** (the protein, an enzyme), not **BCAT1-DT** (the non-coding RNA). If your interest is in the protein BCAT1, it is a validated therapeutic target and biomarker in multiple cancers, but information cannot be directly transferred to its divergent transcript.

Other names

lnc-BCAT1BCAT1 divergent transcriptBCAT1-DT

Not applicable. No drugs have established mechanisms of action via BCAT1-DT.